Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Disease crawled time : 10:00 save search
Novo Nordisk to acquire Cardior Pharmaceuticals and strengthen pipeline in cardiovascular disease
Published: 2024-03-25 (Crawled : 10:00) - globenewswire.com
NVO | News | $122.71 -0.03% 0.17% 5M
|
Health Technology
|
| O: 0.19%
H: 0.97%
C: 0.04%
disease pipeline pharmaceuticals acquire cardiovascular
Novo Nordisk A/S: Semaglutide 1.0 mg demonstrates 24% reduction in the risk of kidney disease-related events in people with type 2 diabetes and chronic kidney disease in the FLOW trial
Published: 2024-03-05 (Crawled : 10:00) - globenewswire.com
NVO | News | $122.71 -0.03% 0.17% 5M
|
Health Technology
|
| O: -1.33%
H: 0.46%
C: -1.27%
disease kidney risk trial diabetes flow
Vertex & CRISPR Therapeutics Announce Authorization of the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), by the United Kingdom MHRA for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
Published: 2023-11-16 (Crawled : 10:00) - biospace.com/
VRTX | News | $394.43 0.24% 0.24% 1.3M
|
Health Technology
|
| O: 0.4%
H: 0.38%
C: -2.2%
CRSP M | $55.04 -1.99% -2.03% 1.8M
|
Health Technology
|
| O: 3.25%
H: 4.05%
C: 2.0%
crispr disease authorization cell treatment therapeutics
Beam Announces Agreement for Lilly to Acquire Beam’s Opt-In Rights to Verve Therapeutics’ Base Editing Programs for Cardiovascular Disease
Published: 2023-10-31 (Crawled : 10:00) - globenewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.03%
H: 0.0%
C: 0.0%
BEAM | $23.9 -1.69% -1.72% 4.5M
|
Health Technology
|
| O: 7.69%
H: 7.3%
C: 2.72%
disease acquire cardiovascular agreement
Redefining Colorectal Cancer (CRC) Landscape Report with DLI's Epidemiology Study, Drug Insights, Price Reimbursement, and Regulatory Consulting Services | Disease Landscape Insights
Published: 2023-10-09 (Crawled : 10:00) - prnewswire.com
ILMN | $117.43 0.63% 0.63% 1.4M
|
Health Technology
|
| O: -0.99%
H: 0.56%
C: -0.61%
EXAS | $60.97 -3.95% -4.12% 2.2M
|
Health Technology
|
| O: -0.29%
H: 3.53%
C: 3.1%
drug disease services report cancer
Phase III studies to investigate survodutide for people living with obesity and overweight, with and without diabetes, cardiovascular disease and chronic kidney disease
Published: 2023-10-05 (Crawled : 10:00) - globenewswire.com
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.4%
H: 0.0%
C: 0.0%
obesity disease kidney cardiovascular living
Innovations in Tonsillitis Disease Landscape Report: DLI's Extensive Disease Insights, Unmet Needs Analysis, KOL Perspectives, Epidemiology Study, and Regulatory Consulting Services | Disease Landscape Insights
Published: 2023-10-03 (Crawled : 10:00) - prnewswire.com
QDEL | News M | $39.09 2.17% 2.12% 1.1M
|
Health Technology
|
| O: -0.62%
H: 1.52%
C: 1.0%
disease services
Global Autoimmune Disease Diagnostics Research Analysis Report 2023-2030: From Cells to Systems - Unveiling the Complexities of Autoimmune Disease Diagnostics
Published: 2023-08-24 (Crawled : 10:00) - prnewswire.com
ABT | News | $107.28 1.91% 0.18% 10M
|
Health Technology
|
| O: -0.59%
H: 0.0%
C: 0.0%
disease report research global diagnostics
Belite Bio Completes Enrollment in Pivotal Global Phase 3 DRAGON Trial Evaluating Oral Tinlarebant for Stargardt Disease
Published: 2023-07-24 (Crawled : 10:00) - globenewswire.com
BLTE | $33.49 -3.21% -3.31% 21K
|
n/a
|
| O: 0.17%
H: 7.09%
C: 4.0%
disease global trial
Evotec Receives Milestone Payment for First Patient Dosed in Phase I Study of Bayer Kidney Disease Programme
Published: 2023-06-29 (Crawled : 10:00) - biospace.com/
EVO | $7.15 -0.7% 19K
|
Manufacturing
|
| O: -2.29%
H: 0.54%
C: 0.45%
disease kidney payment milestone study
New Report Reveals Rare Disease Market Worth US$ 547.5 billion, With CAGR of 13.1% - With Innovative treatments and therapies
Published: 2023-05-11 (Crawled : 10:00) - prnewswire.com
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.28%
H: 0.0%
C: 0.0%
rare disease report market
Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce FDA Approval of ELFABRIO® (pegunigalsidase alfa-iwxj) for the Treatment of Fabry Disease
Published: 2023-05-10 (Crawled : 10:00) - prnewswire.com
PLX | $1.15 1.77% -2.61% 450K
|
Health Services
|
| O: 3.42%
H: 2.65%
C: -2.65%
elfabrio fda rare disease approval treatment global
Lilly's Donanemab Significantly Slowed Cognitive and Functional Decline in Phase 3 Study of Early Alzheimer's Disease
Published: 2023-05-03 (Crawled : 10:00) - prnewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 2.68%
H: 4.62%
C: 3.89%
disease alzheimer's study
The Worldwide End Stage Renal Disease Industry is Expected to Reach $261 Billion by 2030
Published: 2022-09-27 (Crawled : 10:00) - prnewswire.com
FMCQF | $42.034 -0.37% 750
|
Health Services
|
| O: 7.23%
H: 0.0%
C: -4.41%
disease renal expected
CANbridge Forms Scientific Advisory Board to Guide Global Development of CAN106 in Complement-mediated Diseases
Published: 2022-07-07 (Crawled : 10:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -1.83%
H: 0.0%
C: -1.19%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.38%
H: 0.64%
C: 0.24%
can106 disease
Global Alzheimer's Disease Treatment Markets, Analysis & Forecasts, 2016-2021, 2021-2026F, 2031F: Focus on Cholinergic, Memantine, Combined Drug, AChE inhibitors, Immunoglobulins
Published: 2022-06-02 (Crawled : 10:00) - prnewswire.com
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: -0.31%
H: 0.0%
C: 0.0%
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: -3.16%
H: 0.36%
C: -0.07%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: -0.73%
H: 0.12%
C: 0.1%
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.9%
H: 0.0%
C: 0.0%
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: 0.21%
H: 0.0%
C: 0.0%
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: -1.0%
H: 0.0%
C: 0.0%
treatment disease alzheimer's alzheimer’s
Insights on Global Infectious Disease Diagnostics Market Size & Share Calculated to Reach USD 42013.2 Million by 2027, Exhibit a CAGR of 6.9%: Report by Zion Market Research
Published: 2022-05-18 (Crawled : 10:00) - prnewswire.com
TMO | News | $544.78 0.6% 0.0% 1.7M
|
Health Technology
|
| O: -0.87%
H: 0.0%
C: 0.0%
DHR | $235.51 -0.36% 0.0% 2.3M
|
Health Technology
|
| O: -1.89%
H: 0.79%
C: -1.38%
BIO | $279.73 -0.46% 0.0% 290K
|
Health Technology
|
| O: -1.3%
H: 0.83%
C: -0.45%
BDX | $234.12 0.42% 0.0% 1.3M
|
Health Technology
|
| O: 0.64%
H: 0.25%
C: -1.84%
ABT | News | $107.28 1.91% 0.18% 10M
|
Health Technology
|
| O: 1.54%
H: 0.0%
C: 0.0%
TRIB | $1.81 -3.72% -3.87% 5.7K
|
Health Technology
|
| O: 0.0%
H: 4.13%
C: -0.83%
QDEL | News M | $39.09 2.17% 2.12% 1.1M
|
Health Technology
|
| O: 0.15%
H: 3.03%
C: -1.59%
HOLX | $75.37 0.36% 0.36% 1.3M
|
Health Technology
|
| O: 1.12%
H: 0.0%
C: 0.0%
CODX | $1.16 4.2% 18K
|
Health Technology
|
| O: 4.38%
H: 1.5%
C: -2.0%
research disease report diagnostics market diagnostic
Incyte Announces European Commission Approval of Jakavi® (ruxolitinib) as the First Post-Steroid Treatment for Acute and Chronic Graft-Versus-Host Disease
Published: 2022-05-05 (Crawled : 10:00) - biospace.com/
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: -0.39%
H: 0.15%
C: -1.07%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: 3.73%
H: 0.09%
C: -3.98%
jakavi treatment disease approval
OMass Therapeutics Raises $100 Million in Series B Financing to Progress Drug Pipeline in Immunology and Rare Diseases
Published: 2022-04-28 (Crawled : 10:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -2.96%
H: 0.0%
C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -2.36%
H: 0.0%
C: 0.0%
rare drug immunology therapeutics disease
Alzheimer's Disease Therapeutics Market 2022-2026 | Availability, Research, and Development of Novel Biomarkers to Boost Growth | Technavio
Published: 2022-04-26 (Crawled : 10:00) - prnewswire.com
VTRS A | $11.25 1.17% 1.16% 4.7M
|
Health Technology
|
| O: 1.72%
H: 1.7%
C: -0.29%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 0.47%
H: 0.83%
C: -1.44%
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 1.32%
H: 0.0%
C: 0.0%
DNLI | $15.98 -3.74% -3.88% 1.5M
|
Health Technology
|
| O: -0.59%
H: 1.72%
C: -7.7%
BIIB | $194.39 2.03% 1.99% 1.6M
|
Health Technology
|
| O: 1.77%
H: 0.71%
C: -2.82%
disease alzheimer's therapeutics growth market alzheimer’s biomarkers
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.